Skip to main content
Fig. 5 | Genome Biology

Fig. 5

From: Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells

Fig. 5

Interpretation of drug responses using single-cell signatures. a Dose response curves for the four selected anti-cancer compounds (cytotoxic compounds carboplatin and docetaxel; molecular targeting compounds DAPT, BKM120, BEZ235, and selumetinib). b Normalized RSs (top) and adjusted-expression of the 69 prognostic markers (middle) with KRAS mutant expression (bottom) for the control and drug-treated PDX cells. c–f Comparative features among the control and drug-treated PDX cells. c KRAS gene expression (Log2 ratio of TPM + 1). Gene set signature scores (computed by gene set variation analysis) corresponding to the KRAS over-expression signature [39] (d), KRAS mutation signature [40] (e), and MAPK pathway signature (gene sets from BioCarta) (f). g Results from the principal component (PC) analysis on single cells along with the control and drug-treated PDX cells. Ellipsoids correspond to the single cell subgroups (group 1, light green; group 2, dark green; group 3, light red; group 4, dark red), with the control and drug-treated PDX cells projected on the PC1-PC2 plane. Using single cell subgroups as a training set, classification support vector machine type 1 (C-SVM classification) was applied to a test set of the control and drug-treated PDX cells

Back to article page